Atherosclerotic Cardiovascular Disease
ICER will review the comparative clinical effectiveness and value of canakinumab (Novartis) for cardiovascular risk reduction in people with atherosclerosis.
Preservation Park (Nile Hall)
668 13th Street, Oakland, CA 94612
Oakland CA, 94612
CTAF will convene to review ICER's assessment of canakinumab for atherosclerosis.
Open to public comment until December 17, 2018. Click here for more information on how to submit a public comment.